BACKGROUND: Approaches to safely induce tolerance in vascularized composite allotransplantation (VCA) with chimerism through bone marrow transplantation (BMT) are currently being pursued. However, VCA was historically performed sequentially after donor chimerism was established. Delayed VCA is not clinically applicable due to the time constraints associated with procurement from deceased donors. A more clinically relevant approach to perform both BMT and VCA simultaneously was evaluated. METHODS: Wistar Furth (RT1A) rats were treated with a short course of immunosuppressive therapy (anti-αβ-TCR monoclonal antibody, FK-506, and anti-lymphocyte serum). One day before BMT, rats were treated with varying doses of total body irradiation (TBI) followed by transplantation of heterotopic osteomyocutaneous flaps from hindlimbs of August Copenhagen Irish (RT1A) rats. RESULTS: Eighty percent of rats conditioned with 300 cGy TBI and 40% of rats receiving 400 cGy TBI accepted the VCA. Mixed chimerism was detected in peripheral blood at 1 month after VCA, but chimerism was lost in all transplant recipients by 4 months. Most peripheral donor cells originated from the BMT and not from the VCA. Acceptors of VCA were tolerant of a donor skin graft challenge and no anti-donor antibodies were detectable, suggesting a central deletional mechanism for tolerance. Regulatory T cells (Treg) from spleens of acceptors more potently suppressed lymphocyte proliferation than Treg from rejectors in the presence of donor stimulator cells. CONCLUSIONS: These studies suggest that simultaneous BMT and VCA may establish indefinite allograft survival in rats through Treg-mediated suppression and thymic deletion of alloreactive T cells.
BACKGROUND: Approaches to safely induce tolerance in vascularized composite allotransplantation (VCA) with chimerism through bone marrow transplantation (BMT) are currently being pursued. However, VCA was historically performed sequentially after donor chimerism was established. Delayed VCA is not clinically applicable due to the time constraints associated with procurement from deceased donors. A more clinically relevant approach to perform both BMT and VCA simultaneously was evaluated. METHODS: Wistar Furth (RT1A) rats were treated with a short course of immunosuppressive therapy (anti-αβ-TCR monoclonal antibody, FK-506, and anti-lymphocyte serum). One day before BMT, rats were treated with varying doses of total body irradiation (TBI) followed by transplantation of heterotopic osteomyocutaneous flaps from hindlimbs of August Copenhagen Irish (RT1A) rats. RESULTS: Eighty percent of rats conditioned with 300 cGy TBI and 40% of rats receiving 400 cGy TBI accepted the VCA. Mixed chimerism was detected in peripheral blood at 1 month after VCA, but chimerism was lost in all transplant recipients by 4 months. Most peripheral donor cells originated from the BMT and not from the VCA. Acceptors of VCA were tolerant of a donor skin graft challenge and no anti-donor antibodies were detectable, suggesting a central deletional mechanism for tolerance. Regulatory T cells (Treg) from spleens of acceptors more potently suppressed lymphocyte proliferation than Treg from rejectors in the presence of donor stimulator cells. CONCLUSIONS: These studies suggest that simultaneous BMT and VCA may establish indefinite allograft survival in rats through Treg-mediated suppression and thymic deletion of alloreactive T cells.
Authors: Joseph Leventhal; Michael Abecassis; Joshua Miller; Lorenzo Gallon; Kadiyala Ravindra; David J Tollerud; Bradley King; Mary Jane Elliott; Geoffrey Herzig; Roger Herzig; Suzanne T Ildstad Journal: Sci Transl Med Date: 2012-03-07 Impact factor: 17.956
Authors: T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung Journal: Hepatology Date: 1993-06 Impact factor: 17.425
Authors: Shoba Amarnath; Carliann M Costanzo; Jacopo Mariotti; Jessica L Ullman; William G Telford; Veena Kapoor; James L Riley; Bruce L Levine; Carl H June; Timothy Fong; Noel L Warner; Daniel H Fowler Journal: PLoS Biol Date: 2010-02-02 Impact factor: 8.029
Authors: Warren C Breidenbach; N Ruben Gonzales; Christina L Kaufman; Martin Klapheke; Gordon R Tobin; Vijay S Gorantla Journal: J Hand Surg Am Date: 2008-09 Impact factor: 2.230
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: John D Scandling; Stephan Busque; Sussan Dejbakhsh-Jones; Claudia Benike; Maria T Millan; Judith A Shizuru; Richard T Hoppe; Robert Lowsky; Edgar G Engleman; Samuel Strober Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: David W Mathes; Jeff Chang; Billanna Hwang; Scott S Graves; Barry E Storer; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb Journal: Transplantation Date: 2014-07-27 Impact factor: 4.939
Authors: Wakako Tsuji; Jonas T Schnider; Meghan M McLaughlin; Riccardo Schweizer; Wensheng Zhang; Mario G Solari; J Peter Rubin; Kacey G Marra; Jan A Plock; Vijay S Gorantla Journal: Front Immunol Date: 2015-04-16 Impact factor: 7.561